Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors

PURPOSE: AUY922 is a potent non-geldanamycin inhibitor of heat-shock protein 90. This study was carried out in Japanese patients to determine the maximum tolerated dose (MTD), and to characterize safety, tolerability and pharmacokinetics of single-agent AUY922. METHODS: Japanese patients with advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Toshihiko, Onozawa, Yusuke, Fuse, Nozomu, Yoshino, Takayuki, Yamazaki, Kentaro, Watanabe, Junichiro, Akimov, Mikhail, Robson, Matthew, Boku, Narikazu, Ohtsu, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143601/
https://www.ncbi.nlm.nih.gov/pubmed/25059319
http://dx.doi.org/10.1007/s00280-014-2521-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143601/
https://www.ncbi.nlm.nih.gov/pubmed/25059319
http://dx.doi.org/10.1007/s00280-014-2521-x

Ejemplares similares